| Year |
Citation |
Score |
| 2023 |
Stamatatos L. 'Immunization during ART and ATI for HIV-1 vaccine discovery/development'. Current Opinion in Hiv and Aids. PMID 37712859 DOI: 10.1097/COH.0000000000000817 |
0.558 |
|
| 2023 |
Bale S, Yang L, Alirezaei M, Wilson R, Ota T, Doyle ED, Cottrell CA, Guenaga J, Tran K, Li W, Stamatatos L, Nemazee D, Ward AB, Wyatt RT. Fusion of the molecular adjuvant C3d to cleavage-independent native-like HIV-1 Env trimers improves the elicited antibody response. Frontiers in Immunology. 14: 1180959. PMID 37283743 DOI: 10.3389/fimmu.2023.1180959 |
0.541 |
|
| 2023 |
Gristick HB, Hartweger H, Loewe M, van Schooten J, Ramos V, Oliveira TY, Nishimura Y, Koranda NS, Wall A, Yao KH, Poston D, Gazumyan A, Wiatr M, Horning M, Keeffe JR, ... ... Stamatatos L, et al. CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals. Science Immunology. 8: eade6364. PMID 36763635 DOI: 10.1126/sciimmunol.ade6364 |
0.64 |
|
| 2022 |
Hägglöf T, Cipolla M, Loewe M, Chen ST, Mesin L, Hartweger H, ElTanbouly MA, Cho A, Gazumyan A, Ramos V, Stamatatos L, Oliveira TY, Nussenzweig MC, Viant C. Continuous germinal center invasion contributes to the diversity of the immune response. Cell. PMID 36565698 DOI: 10.1016/j.cell.2022.11.032 |
0.33 |
|
| 2022 |
Knudsen ML, Agrawal P, MacCamy A, Parks KR, Gray MD, Takushi BN, Khechaduri A, Salladay KR, Coler RN, LaBranche CC, Montefiori D, Stamatatos L. Adjuvants influence the maturation of VRC01-like antibodies during immunization. Iscience. 25: 105473. PMID 36405776 DOI: 10.1016/j.isci.2022.105473 |
0.42 |
|
| 2022 |
Noto A, Suffiotti M, Joo V, Mancarella A, Procopio FA, Cavet G, Leung Y, Corpataux JM, Cavassini M, Riva A, Stamatatos L, Gottardo R, McDermott AB, Koup RA, Fenwick C, et al. The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection. Frontiers in Immunology. 13: 960120. PMID 36091040 DOI: 10.3389/fimmu.2022.960120 |
0.316 |
|
| 2022 |
Gray MD, Feng J, Weidle CE, Cohen KW, Ballweber-Fleming L, MacCamy AJ, Huynh CN, Trichka JJ, Montefiori D, Ferrari G, Pancera M, McElrath MJ, Stamatatos L. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. Science Advances. 8: eabm3948. PMID 35507661 DOI: 10.1126/sciadv.abm3948 |
0.497 |
|
| 2022 |
Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan YH, Boonyaratanakornkit J, Sholukh AM, Jackson AM, Zhou P, Burton DR, Andrabi R, Ozorowski G, Ward AB, Stamatatos L, et al. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Communications Biology. 5: 342. PMID 35411021 DOI: 10.1038/s42003-022-03262-7 |
0.353 |
|
| 2022 |
Beaudoin-Bussières G, Chen Y, Ullah I, Prévost J, Tolbert WD, Symmes K, Ding S, Benlarbi M, Gong SY, Tauzin A, Gasser R, Chatterjee D, Vézina D, Goyette G, Richard J, ... ... Stamatatos L, et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Reports. 38: 110368. PMID 35123652 DOI: 10.1016/j.celrep.2022.110368 |
0.485 |
|
| 2021 |
Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, Diaz Avalos R, Zyla D, Buck T, Hui S, Shaffer K, ... ... Stamatatos L, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science (New York, N.Y.). eabh2315. PMID 34554826 DOI: 10.1126/science.abh2315 |
0.355 |
|
| 2021 |
Ullah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Symmes K, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, ... ... Stamatatos L, et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. PMID 34453881 DOI: 10.1016/j.immuni.2021.08.015 |
0.334 |
|
| 2021 |
Seydoux E, Wan YH, Feng J, Wall A, Aljedani S, Homad LJ, MacCamy AJ, Weidle C, Gray MD, Brumage L, Taylor JJ, Pancera M, Stamatatos L, McGuire AT. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. Cell Reports. 36: 109454. PMID 34289363 DOI: 10.1016/j.celrep.2021.109454 |
0.409 |
|
| 2021 |
Sholukh AM, Fiore-Gartland A, Ford ES, Miner MD, Hou YJ, Tse LV, Kaiser H, Zhu H, Lu J, Madarampalli B, Park A, Lempp FA, St Germain R, Bossard EL, Kee JJ, ... ... Stamatatos L, et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. Journal of Clinical Microbiology. JCM0052721. PMID 34288726 DOI: 10.1128/JCM.00527-21 |
0.321 |
|
| 2021 |
Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, ... ... Stamatatos L, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports. 109353. PMID 34237283 DOI: 10.1016/j.celrep.2021.109353 |
0.501 |
|
| 2021 |
Seydoux E, Wan YH, Feng J, Wall A, Aljedani S, Homad LJ, MacCamy AJ, Weidle C, Gray MD, Brumage L, Taylor JJ, Pancera M, Stamatatos L, McGuire AT. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. Cell Reports. 35: 109084. PMID 33951425 DOI: 10.1016/j.celrep.2021.109084 |
0.508 |
|
| 2021 |
Divine R, Dang HV, Ueda G, Fallas JA, Vulovic I, Sheffler W, Saini S, Zhao YT, Raj IX, Morawski PA, Jennewein MF, Homad LJ, Wan YH, Tooley MR, Seeger F, ... ... Stamatatos L, et al. Designed proteins assemble antibodies into modular nanocages. Science (New York, N.Y.). 372. PMID 33795432 DOI: 10.1126/science.abd9994 |
0.418 |
|
| 2021 |
Ullah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, Bourassa C, ... ... Stamatatos L, et al. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. Biorxiv : the Preprint Server For Biology. PMID 33791699 DOI: 10.1101/2021.03.22.436337 |
0.36 |
|
| 2021 |
Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, ... ... Stamatatos L, et al. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. Biorxiv : the Preprint Server For Biology. PMID 33791692 DOI: 10.1101/2021.03.23.436684 |
0.515 |
|
| 2021 |
Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos MP, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science (New York, N.Y.). PMID 33766944 DOI: 10.1126/science.abg9175 |
0.437 |
|
| 2021 |
Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos MP, et al. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Medrxiv : the Preprint Server For Health Sciences. PMID 33758873 DOI: 10.1101/2021.02.05.21251182 |
0.453 |
|
| 2020 |
Sholukh AM, Fiore-Gartland A, Ford ES, Hou Y, Tse LV, Lempp FA, Kaiser H, Saint Germain R, Bossard E, Kee JJ, Diem K, Stuart AB, Rupert PB, Brock C, Buerger M, ... ... Stamatatos L, et al. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials. Medrxiv : the Preprint Server For Health Sciences. PMID 33330875 DOI: 10.1101/2020.12.07.20245431 |
0.353 |
|
| 2020 |
Divine R, Dang HV, Ueda G, Fallas JA, Vulovic I, Sheffler W, Saini S, Zhao YT, Raj IX, Morawski PA, Jennewein MF, Homad LJ, Wan YH, Tooley MR, Seeger F, ... ... Stamatatos L, et al. Designed proteins assemble antibodies into modular nanocages. Biorxiv : the Preprint Server For Biology. PMID 33299994 DOI: 10.1101/2020.12.01.406611 |
0.449 |
|
| 2020 |
Ding S, Laumaea A, Benlarbi M, Beaudoin-Bussières G, Gasser R, Medjahed H, Pancera M, Stamatatos L, McGuire AT, Bazin R, Finzi A. Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. Viruses. 12. PMID 33114742 DOI: 10.3390/v12111214 |
0.389 |
|
| 2020 |
Hurlburt NK, Seydoux E, Wan YH, Edara VV, Stuart AB, Feng J, Suthar MS, McGuire AT, Stamatatos L, Pancera M. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nature Communications. 11: 5413. PMID 33110068 DOI: 10.1038/s41467-020-19231-9 |
0.405 |
|
| 2020 |
Lin YR, Parks KR, Weidle C, Naidu AS, Khechaduri A, Riker AO, Takushi B, Chun JH, Borst AJ, Veesler D, Stuart A, Agrawal P, Gray M, Pancera M, Huang PS, ... Stamatatos L, et al. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors. Immunity. 53: 840-851.e6. PMID 33053332 DOI: 10.1016/j.immuni.2020.09.007 |
0.467 |
|
| 2020 |
Ding S, Laumaea A, Gasser R, Medjahed H, Pancera M, Stamatatos L, McGuire A, Bazin R, Finzi A. Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization. Biorxiv : the Preprint Server For Biology. PMID 32935094 DOI: 10.1101/2020.09.08.287482 |
0.391 |
|
| 2020 |
Hurlburt NK, Wan YH, Stuart AB, Feng J, McGuire AT, Stamatatos L, Pancera M. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Biorxiv : the Preprint Server For Biology. PMID 32577631 DOI: 10.1101/2020.06.12.148692 |
0.369 |
|
| 2020 |
Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Whaley RE, Singh S, Boeckh M, Cohen KW, McElrath MJ, ... ... Stamatatos L, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. PMID 32561270 DOI: 10.1016/J.Immuni.2020.06.001 |
0.612 |
|
| 2020 |
Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Nelson RE, Singh S, Cohen KW, McElrath MJ, Englund JA, ... ... Stamatatos L, et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. Biorxiv : the Preprint Server For Biology. PMID 32511342 DOI: 10.1101/2020.05.12.091298 |
0.541 |
|
| 2019 |
Parks KR, MacCamy AJ, Trichka J, Gray M, Weidle C, Borst AJ, Khechaduri A, Takushi B, Agrawal P, Guenaga J, Wyatt RT, Coler R, Seaman M, LaBranche C, Montefiori DC, ... ... Stamatatos L, et al. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Cell Reports. 29: 3060-3072.e7. PMID 31801073 DOI: 10.1016/J.Celrep.2019.10.071 |
0.656 |
|
| 2019 |
Dosenovic P, Pettersson AK, Wall A, Thientosapol ES, Feng J, Weidle C, Bhullar K, Kara EE, Hartweger H, Pai JA, Gray MD, Parks KR, Taylor JJ, Pancera M, Stamatatos L, et al. Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. The Journal of Experimental Medicine. PMID 31345931 DOI: 10.1084/Jem.20190446 |
0.682 |
|
| 2019 |
Bancroft T, DeBuysscher BL, Weidle C, Schwartz A, Wall A, Gray MD, Feng J, Steach HR, Fitzpatrick KS, Gewe MM, Skog PD, Doyle-Cooper C, Ota T, Strong RK, Nemazee D, ... ... Stamatatos L, et al. Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. The Journal of Experimental Medicine. PMID 31345930 DOI: 10.2210/Pdb6Ol5/Pdb |
0.648 |
|
| 2019 |
Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, ... ... Stamatatos L, et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. PMID 31142836 DOI: 10.1038/S41586-019-1250-Z |
0.692 |
|
| 2019 |
Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. The Journal of Experimental Medicine. PMID 30975893 DOI: 10.1084/Jem.20190287 |
0.638 |
|
| 2019 |
LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, ... ... Stamatatos L, et al. Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. Plos Pathogens. 15: e1007646. PMID 30913265 DOI: 10.1371/journal.ppat.1007646 |
0.557 |
|
| 2018 |
Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, ... ... Stamatatos L, et al. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity. PMID 30552024 DOI: 10.1016/J.Immuni.2018.10.015 |
0.606 |
|
| 2018 |
Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, DiMaio F, Stamatatos L, Pancera M, Veesler D. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. Elife. 7. PMID 30403372 DOI: 10.2210/Pdb6Mft/Pdb |
0.654 |
|
| 2018 |
LaBranche CC, McGuire AT, Gray MD, Behrens S, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Mascola JR, Haynes BF, ... Stamatatos L, et al. HIV-1 Envelope Glycan Modifications that Permit Neutralization by Germline-Reverted VRC01-Class Broadly Neutralizing Antibodies. Plos Pathogens. 14: e1007431. PMID 30395637 DOI: 10.1371/Journal.Ppat.1007431 |
0.691 |
|
| 2018 |
Virnik K, Nesti E, Dail C, Scanlan A, Medvedev A, Vassell R, McGuire AT, Stamatatos L, Berkower I. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. Vaccine. PMID 30037665 DOI: 10.1016/J.Vaccine.2018.07.010 |
0.681 |
|
| 2018 |
Yacoob C, Lange MD, Cohen K, Lathia K, Feng J, Glenn J, Carbonetti S, Oliver B, Vigdorovich V, Sather DN, Stamatatos L. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. Plos Pathogens. 14: e1007120. PMID 29933399 DOI: 10.1371/Journal.Ppat.1007120 |
0.643 |
|
| 2018 |
Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29666227 DOI: 10.1073/Pnas.1803457115 |
0.59 |
|
| 2018 |
Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, DiMaio F, Stamatatos L, Pancera M, Veesler D. Author response: Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core Elife. DOI: 10.7554/Elife.37688.042 |
0.658 |
|
| 2017 |
Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, et al. Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. Cell Reports. 21: 3243-3255. PMID 29241550 DOI: 10.1016/J.Celrep.2017.11.056 |
0.476 |
|
| 2017 |
Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, ... ... Stamatatos L, et al. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of Experimental Medicine. PMID 28847869 DOI: 10.1084/Jem.20161160 |
0.641 |
|
| 2017 |
Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, ... ... Stamatatos L, et al. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Reports. 19: 719-732. PMID 28445724 DOI: 10.1016/J.Celrep.2017.04.013 |
0.656 |
|
| 2017 |
Stamatatos L, Pancera M, McGuire AT. Germline-targeting immunogens. Immunological Reviews. 275: 203-216. PMID 28133796 DOI: 10.1111/Imr.12483 |
0.582 |
|
| 2016 |
Yacoob C, Pancera M, Vigdorovich V, Oliver BG, Glenn JA, Feng J, Sather DN, McGuire AT, Stamatatos L. Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Reports. 17: 1560-1570. PMID 27806295 DOI: 10.1016/J.Celrep.2016.10.017 |
0.707 |
|
| 2016 |
Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, Sheng Z, Kimble M, Wang L, Lin S, Schmidt SD, Du Z, Joyce MG, Chen Y, DeKosky BJ, ... ... Stamatatos L, et al. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell. 166: 1471-1484.e18. PMID 27610571 DOI: 10.1016/J.Cell.2016.07.029 |
0.682 |
|
| 2016 |
Vigdorovich V, Oliver BG, Carbonetti S, Dambrauskas N, Lange MD, Yacoob C, Leahy W, Callahan J, Stamatatos L, Sather DN. Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing. Clinical & Translational Immunology. 5: e93. PMID 27525066 DOI: 10.1038/Cti.2016.42 |
0.332 |
|
| 2016 |
Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ. Structural basis for germline antibody recognition of HIV-1 immunogens. Elife. 5. PMID 26997349 DOI: 10.7554/Elife.13783 |
0.642 |
|
| 2016 |
Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, ... ... Stamatatos L, et al. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. Journal of Immunology (Baltimore, Md. : 1950). PMID 26944928 DOI: 10.4049/Jimmunol.1500527 |
0.615 |
|
| 2016 |
McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, ... Stamatatos L, et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nature Communications. 7: 10618. PMID 26907590 DOI: 10.1038/Ncomms10618 |
0.599 |
|
| 2016 |
Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ. Author response: Structural basis for germline antibody recognition of HIV-1 immunogens Elife. DOI: 10.7554/Elife.13783.028 |
0.676 |
|
| 2015 |
McGuire AT, Stamatatos L. Common Characteristics of HIV-Neutralizing Antibodies with a Fondness for Sugars. Immunity. 43: 837-40. PMID 26588775 DOI: 10.1016/J.Immuni.2015.10.026 |
0.658 |
|
| 2015 |
Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, ... ... Stamatatos L, et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 161: 1505-15. PMID 26091035 DOI: 10.1016/J.Cell.2015.06.003 |
0.718 |
|
| 2015 |
Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, ... ... Stamatatos L, et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 161: 1280-92. PMID 26004070 DOI: 10.1016/J.Cell.2015.05.007 |
0.663 |
|
| 2015 |
McGuire AT, Glenn JA, Lippy A, Stamatatos L. Correction for McGuire et al., diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. Journal of Virology. 89: 5194. PMID 25841051 DOI: 10.1128/Jvi.00341-15 |
0.527 |
|
| 2015 |
Cohen KW, Dugast AS, Alter G, McElrath MJ, Stamatatos L. HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN. Journal of Immunology (Baltimore, Md. : 1950). 194: 2769-75. PMID 25667414 DOI: 10.4049/Jimmunol.1400952 |
0.552 |
|
| 2015 |
Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K, Rademeyer C, Gray GE, Williamson C, Stamatatos L, Seaman MS, et al. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. Journal of Virology. 89: 2507-19. PMID 25540368 DOI: 10.1128/Jvi.03331-14 |
0.558 |
|
| 2015 |
Chang HW, Tartaglia LJ, Whitney JB, Lim SY, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K, Stamatatos L, Kublin J, Barouch DH. Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. Journal of Virology. 89: 1965-74. PMID 25473043 DOI: 10.1128/Jvi.03279-14 |
0.56 |
|
| 2014 |
McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science (New York, N.Y.). 346: 1380-3. PMID 25504724 DOI: 10.1126/Science.1259206 |
0.734 |
|
| 2014 |
Finton KA, Friend D, Jaffe J, Gewe M, Holmes MA, Larman HB, Stuart A, Larimore K, Greenberg PD, Elledge SJ, Stamatatos L, Strong RK. Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. Plos Pathogens. 10: e1004403. PMID 25254371 DOI: 10.1371/Journal.Ppat.1004403 |
0.568 |
|
| 2014 |
Cohen K, Altfeld M, Alter G, Stamatatos L. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. Journal of Virology. 88: 13310-21. PMID 25210168 DOI: 10.1128/Jvi.02186-14 |
0.592 |
|
| 2014 |
Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. Journal of Virology. 88: 12968-81. PMID 25122781 DOI: 10.1128/Jvi.01816-14 |
0.855 |
|
| 2014 |
Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. European Journal of Immunology. 44: 2925-37. PMID 25043633 DOI: 10.1002/Eji.201344305 |
0.868 |
|
| 2014 |
Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. Plos Pathogens. 10: e1004103. PMID 24788925 DOI: 10.1371/Journal.Ppat.1004103 |
0.433 |
|
| 2014 |
Carbonetti S, Oliver BG, Glenn J, Stamatatos L, Sather DN. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. Plos One. 9: e86905. PMID 24466285 DOI: 10.1371/Journal.Pone.0086905 |
0.7 |
|
| 2014 |
McGuire AT, Glenn JA, Lippy A, Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. Journal of Virology. 88: 2645-57. PMID 24352455 DOI: 10.1128/Jvi.03228-13 |
0.684 |
|
| 2013 |
Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, Lee T, West AP, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. The Journal of Experimental Medicine. 210: 1235-49. PMID 23712429 DOI: 10.1084/Jem.20130221 |
0.656 |
|
| 2013 |
Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, ... Stamatatos L, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science (New York, N.Y.). 340: 711-6. PMID 23539181 DOI: 10.1126/Science.1234150 |
0.581 |
|
| 2013 |
McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. The Journal of Experimental Medicine. 210: 655-63. PMID 23530120 DOI: 10.1084/Jem.20122824 |
0.717 |
|
| 2013 |
Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. Plos Pathogens. 9: e1003106. PMID 23300456 DOI: 10.1371/Journal.Ppat.1003106 |
0.673 |
|
| 2013 |
Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L. Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs Plos Pathogens. 9. DOI: 10.1371/Annotation/Ed7C0148-97Eb-4416-824D-6E6D1Aaeceef |
0.533 |
|
| 2013 |
Diskin R, Sather DN, Marcovecchio PM, Lee T, West AP, Gao H, Klein F, -Halper-Stromberg A, Horwitz J, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ. D106 Overcoming HIV pathways for escape using rationally-designed anti-HIV antibodies Jaids Journal of Acquired Immune Deficiency Syndromes. 62: S49. DOI: 10.1097/01.Qai.0000429234.07501.Af |
0.679 |
|
| 2012 |
Mikell I, Stamatatos L. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. Plos One. 7: e49610. PMID 23152926 DOI: 10.1371/Journal.Pone.0049610 |
0.881 |
|
| 2012 |
Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid JF, Klein F, Stamatatos L. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. Journal of Virology. 86: 12676-85. PMID 22973035 DOI: 10.1128/Jvi.01893-12 |
0.866 |
|
| 2012 |
McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. Plos One. 7: e41832. PMID 22848626 DOI: 10.1371/Journal.Pone.0041832 |
0.414 |
|
| 2012 |
Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, ... ... Stamatatos L, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. The Journal of Experimental Medicine. 209: 1469-79. PMID 22826297 DOI: 10.1084/Jem.20120423 |
0.72 |
|
| 2012 |
Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine. 30: 5519-26. PMID 22749601 DOI: 10.1016/J.Vaccine.2012.06.042 |
0.67 |
|
| 2012 |
Stamatatos L. HIV vaccine design: the neutralizing antibody conundrum. Current Opinion in Immunology. 24: 316-23. PMID 22595693 DOI: 10.1016/J.Coi.2012.04.006 |
0.62 |
|
| 2012 |
Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. Journal of Virology. 86: 128-42. PMID 22031951 DOI: 10.1128/Jvi.06363-11 |
0.576 |
|
| 2012 |
McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ. Correction: Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation Plos One. 7. DOI: 10.1371/Annotation/78Ba072A-6B7A-430A-8Fcd-Ef020E4Fc458 |
0.476 |
|
| 2012 |
Malherbe D, Hessell A, Sather N, Guo B, Pandey S, Pissani F, Robins H, Kalams S, Stamatatos L, Haigwood N. Native envelope-based immunogens derived from critical timepoints in the development of breadth elicit rapid neutralizing antibodies in rabbits Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P345 |
0.555 |
|
| 2012 |
Finton K, Larmen B, Larimore K, Stuart A, Friend D, Vanden Bos T, Greenberg P, Elledge S, Stamatatos L, Strong R. Functional properties of an ensemble of candidate germline-encoded precursors of the anti-MPER antibody 4E10 Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P344 |
0.619 |
|
| 2012 |
Hoot SJ, Stamatatos L. 111 Interactions Between HIV Env and Germline Versions of bNAbs Jaids Journal of Acquired Immune Deficiency Syndromes. 59: 45. DOI: 10.1097/01.Qai.0000413730.22234.57 |
0.53 |
|
| 2011 |
Shah A, Verma AS, Patel KH, Noel R, Rivera-Amill V, Silverstein PS, Chaudhary S, Bhat HK, Stamatatos L, Singh DP, Buch S, Kumar A. HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. Plos One. 6: e21261. PMID 21712995 DOI: 10.1371/Journal.Pone.0021261 |
0.44 |
|
| 2011 |
Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. Journal of Virology. 85: 7095-107. PMID 21543501 DOI: 10.1128/Jvi.00411-11 |
0.66 |
|
| 2011 |
Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, Barnett S, Stamatatos L, Haigwood NL. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. Journal of Virology. 85: 5262-74. PMID 21430056 DOI: 10.1128/Jvi.02419-10 |
0.657 |
|
| 2011 |
Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. Journal of Virology. 85: 4578-85. PMID 21325411 DOI: 10.1128/Jvi.02585-10 |
0.727 |
|
| 2011 |
Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. Plos Pathogens. 7: e1001251. PMID 21249232 DOI: 10.1371/Journal.Ppat.1001251 |
0.877 |
|
| 2011 |
Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. Journal of Virology. 85: 2524-35. PMID 21191009 DOI: 10.1128/Jvi.02335-10 |
0.64 |
|
| 2011 |
Correia BE, Ban YE, Friend DJ, Ellingson K, Xu H, Boni E, Bradley-Hewitt T, Bruhn-Johannsen JF, Stamatatos L, Strong RK, Schief WR. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. Journal of Molecular Biology. 405: 284-97. PMID 20969873 DOI: 10.1016/J.Jmb.2010.09.061 |
0.447 |
|
| 2011 |
Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Correction: Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 Plos Pathogens. 7. DOI: 10.1371/Annotation/8B3B24B5-D4Ed-483A-B233-0A88513Ad499 |
0.865 |
|
| 2011 |
Mikell I, Sather DN, Kalams S, Altfeld M, Alter G, Stamatatos L. 141 Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 Journal of Acquired Immune Deficiency Syndromes. 56: 57. DOI: 10.1097/01.Qai.0000397327.26622.5C |
0.866 |
|
| 2010 |
Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, ... ... Stamatatos L, et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure (London, England : 1993). 18: 1116-26. PMID 20826338 DOI: 10.1016/J.Str.2010.06.010 |
0.675 |
|
| 2010 |
Ching L, Stamatatos L. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop. Journal of Virology. 84: 9932-46. PMID 20660181 DOI: 10.1128/Jvi.00868-10 |
0.814 |
|
| 2010 |
Sather DN, Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine. 28: B8-12. PMID 20510750 DOI: 10.1016/J.Vaccine.2009.07.085 |
0.729 |
|
| 2010 |
Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of Virology. 84: 3443-53. PMID 20106929 DOI: 10.1128/Jvi.02617-09 |
0.732 |
|
| 2010 |
Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, Srivastava I, Barnett SW, Cleveland B, Overbaugh J, Hu SL. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. Journal of Virology. 84: 2573-84. PMID 20015987 DOI: 10.1128/Jvi.01687-09 |
0.725 |
|
| 2010 |
Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, Reinherz EL, Stamatatos L, Strong RK. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. Journal of Virology. 84: 1076-88. PMID 19906921 DOI: 10.1128/Jvi.02113-09 |
0.481 |
|
| 2009 |
Schief WR, Ban YE, Stamatatos L. Challenges for structure-based HIV vaccine design. Current Opinion in Hiv and Aids. 4: 431-40. PMID 20048708 DOI: 10.1097/Coh.0B013E32832E6184 |
0.564 |
|
| 2009 |
Sellhorn G, Caldwell Z, Mineart C, Stamatatos L. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine. 28: 430-6. PMID 19857451 DOI: 10.1016/J.Vaccine.2009.10.028 |
0.638 |
|
| 2009 |
Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Medicine. 15: 866-70. PMID 19525964 DOI: 10.1038/Nm.1949 |
0.679 |
|
| 2009 |
Wallace A, Stamatatos L. Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype. Journal of Virology. 83: 7883-93. PMID 19494007 DOI: 10.1128/Jvi.00582-09 |
0.713 |
|
| 2009 |
Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. Journal of Virology. 83: 757-69. PMID 18987148 DOI: 10.1128/Jvi.02036-08 |
0.864 |
|
| 2009 |
Carrico C, Lagerquist E, Boni E, Ban Y, Bretz C, Ellingson K, Kalyuzhniy O, Montefiori D, Strong R, Stamatatos L, Schief W. P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P88 |
0.515 |
|
| 2009 |
Malherbe D, Doria-Rose N, Misher L, Beckett T, Blay-Puryear W, Barnett S, Srivastava I, Richardson B, Stamatatos L, Haigwood N. P05-10. Sequential immunization with a subtype B HIV-1 envelope quasispecies elicits broader neutralization than vaccination with a single envelope clone Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P86 |
0.642 |
|
| 2009 |
Ban Y, Correia B, Holmes M, Boni E, Sather N, Bretz C, Kalyuzhniy O, Xu C, Baker D, Stamatatos L, Strong R, Schief W. P05-09. 4e10 epitope-scaffolds mimic the antibody-bound epitope conformation and block neutralization by sera from rare HIV+ individuals Retrovirology. 6: P85. DOI: 10.1186/1742-4690-6-S3-P85 |
0.617 |
|
| 2009 |
Strong R, Boni E, Bradley-Hewitt T, Burke K, Friend D, Holmes M, Hsu C, Zenobia C, Schief W, Stamatatos L. P05-06. Masking of MPER epitopes through self-associations Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P82 |
0.563 |
|
| 2009 |
Tawde P, Strouss K, Kraft Z, Gauduin M, Stamatatos L. P04-24. Frequencies of HIV Env-specific B cells and neutralizing antibodies during DNA-prime/protein-boost immunization with three different Env immunogens* Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P52 |
0.604 |
|
| 2009 |
Mikell I, Sather D, Kalams S, Altfeld M, Stamatatos L. P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P43 |
0.84 |
|
| 2009 |
Sellhon G, Wallace A, Caldwell Z, Lagerquist E, Mineart C, Strousse K, Stamatatos L. P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P362 |
0.371 |
|
| 2009 |
Ching LK, Stamatatos L. P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P326 |
0.838 |
|
| 2009 |
Xu H, Scherer E, Song L, Kim M, Holmes M, Sellhorn G, Kraft Z, Reinherz E, Burton D, Stamatatos L, Strong R. P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P32 |
0.644 |
|
| 2009 |
Sather D, Kraft Z, Stamatatos L. P09-06. HIV-1 escape from broadly neutralizing anti-CD4 binding site NAbs during HIV-1 infection Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P119 |
0.609 |
|
| 2009 |
Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection (Journal of Virology (2009) 83, 2 (757-769)) Journal of Virology. 83: 4713-4715. DOI: 10.1128/Jvi.00283-09 |
0.795 |
|
| 2008 |
Polacino P, Larsen K, Galmin L, Suschak J, Kraft Z, Stamatatos L, Anderson D, Barnett SW, Pal R, Bost K, Bandivdekar AH, Miller CJ, Hu SL. Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. Journal of Medical Primatology. 37: 13-23. PMID 19187427 DOI: 10.1111/J.1600-0684.2008.00325.X |
0.329 |
|
| 2008 |
Kraft Z, Strouss K, Sutton WF, Cleveland B, Tso FY, Polacino P, Overbaugh J, Hu SL, Stamatatos L. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. Journal of Virology. 82: 5912-21. PMID 18400850 DOI: 10.1128/Jvi.00389-08 |
0.604 |
|
| 2008 |
Xu Y, Zhu H, Wilcox CK, van't Wout A, Andrus T, Llewellyn N, Stamatatos L, Mullins JI, Corey L, Zhu T. Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. The Journal of Infectious Diseases. 197: 309-18. PMID 18173363 DOI: 10.1086/524847 |
0.551 |
|
| 2008 |
Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, Barnett SW. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology. 372: 273-90. PMID 18061231 DOI: 10.1016/J.Virol.2007.10.022 |
0.425 |
|
| 2008 |
Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. Journal of Virology. 82: 949-56. PMID 18003732 DOI: 10.1128/Jvi.02143-07 |
0.865 |
|
| 2008 |
Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, Barnett SW. Corrigendum to "Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates" [Virology 372 (2008) 273-290] (DOI:10.1016/j.virol.2007.10.022) Virology. 381: 287. DOI: 10.1016/J.Virol.2008.09.005 |
0.416 |
|
| 2007 |
Hu SL, Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Current Hiv Research. 5: 507-13. PMID 18045108 DOI: 10.2174/157016207782418542 |
0.715 |
|
| 2007 |
Derby NR, Gray S, Wayner E, Campogan D, Vlahogiannis G, Kraft Z, Barnett SW, Srivastava IK, Stamatatos L. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology. 366: 433-45. PMID 17560621 DOI: 10.1016/J.Virol.2007.05.020 |
0.849 |
|
| 2007 |
Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies Journal of Virology. 81: 6402-6411. PMID 17392364 DOI: 10.1128/Jvi.00424-07 |
0.87 |
|
| 2006 |
Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology. 352: 131-44. PMID 21894641 DOI: 10.1016/J.Virol.2006.04.030 |
0.53 |
|
| 2006 |
Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, Stamatatos L. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. Aids Research and Human Retroviruses. 22: 1022-30. PMID 17067273 DOI: 10.1089/Aid.2006.22.1022 |
0.537 |
|
| 2006 |
Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies Virology. 355: 138-151. PMID 16920175 DOI: 10.1016/J.Virol.2006.07.026 |
0.809 |
|
| 2006 |
Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Journal of Virology. 80: 8745-62. PMID 16912322 DOI: 10.1128/Jvi.00956-06 |
0.862 |
|
| 2006 |
Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, Stamatatos L, Shrikant PA, Kozbor D. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. Journal of Immunology (Baltimore, Md. : 1950). 177: 177-91. PMID 16785513 DOI: 10.4049/Jimmunol.177.1.177 |
0.342 |
|
| 2006 |
Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology. 349: 276-89. PMID 16527321 DOI: 10.1016/J.Virol.2006.01.043 |
0.701 |
|
| 2006 |
Srivastava IK, Kan E, Sun Y, Legg H, Lee Q, Burke B, Greer C, Lian Y, Stamatatos L, Ulmer JB, Vajdy M, Donnelly J, Miller C, Barnett SW. Antibody mediated protection of immunized macaques against pathogenic SHIV challenge Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-S27 |
0.566 |
|
| 2005 |
Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology. 79: 10108-25. PMID 16051804 DOI: 10.1128/Jvi.79.16.10108-10125.2005 |
0.693 |
|
| 2005 |
Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner Journal of Virology. 79: 9069-9080. PMID 15994801 DOI: 10.1128/Jvi.79.14.9069-9080.2005 |
0.634 |
|
| 2005 |
Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'keefe BR, McMahon J, Stamatatos L, de Clercq E, Bolmstedt A. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. Journal of Virology. 79: 7777-84. PMID 15919930 DOI: 10.1128/Jvi.79.12.7777-7784.2005 |
0.444 |
|
| 2005 |
Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. Journal of Virology. 79: 5232-7. PMID 15795308 DOI: 10.1128/Jvi.79.8.5232-5237.2005 |
0.679 |
|
| 2004 |
McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. Journal of Virology. 78: 3279-95. PMID 15016849 DOI: 10.1128/Jvi.78.7.3279-3295.2004 |
0.637 |
|
| 2004 |
Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, Gettie A, Bohm R, Blanchard J, Barnett SW, Safrit JT, Stamatatos L. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology. 320: 167-80. PMID 15003872 DOI: 10.1016/J.Virol.2003.12.003 |
0.661 |
|
| 2004 |
Buckner C, Gines LG, Saunders CJ, Vojtech L, Srivastava I, Gettie A, Bohm R, Blanchard J, Barnett SW, Safrit JT, Stamatatos L. Corrigendum to “Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV” [Virology 320 (2004) 167–180] Virology. 325: 164. DOI: 10.1016/J.Virol.2004.05.002 |
0.528 |
|
| 2003 |
Haigwood NL, Stamatatos L. Role of neutralizing antibodies in HIV infection. Aids (London, England). 17: S67-71. PMID 15080182 DOI: 10.1097/00002030-200317004-00008 |
0.705 |
|
| 2003 |
Gummuluru S, Rogel M, Stamatatos L, Emerman M. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. Journal of Virology. 77: 12865-74. PMID 14610207 DOI: 10.1128/Jvi.77.23.12865-12874.2003 |
0.361 |
|
| 2003 |
Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. Journal of Virology. 77: 11244-59. PMID 14512572 DOI: 10.1128/Jvi.77.20.11244-11259.2003 |
0.684 |
|
| 2003 |
Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. Journal of Virology. 77: 2310-20. PMID 12551968 DOI: 10.1128/Jvi.77.4.2310-2320.2003 |
0.617 |
|
| 2002 |
Donnelly JJ, Barnett SW, Dorenbaum A, Stamatatos L. Envelope-based HIV vaccines. Science (New York, N.Y.). 297: 1277-8; author reply. PMID 12194177 DOI: 10.1126/Science.297.5585.1277 |
0.544 |
|
| 2002 |
Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Barnett SW. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. Journal of Virology. 76: 2835-47. PMID 11861851 DOI: 10.1128/JVI.76.6.2835-2847.2002 |
0.52 |
|
| 2002 |
Stamatatos L, Davis D. New insights into protective humoral responses and HIV vaccines. Aids (London, England). S105-15. PMID 11816158 DOI: 10.1097/00002030-200100005-00014 |
0.724 |
|
| 2001 |
Cherpelis S, Jin X, Gettie A, Ho DD, Barnett SW, Shrivastava I, Stamatatos L. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques Immunology Letters. 79: 47-55. PMID 11595289 DOI: 10.1016/S0165-2478(01)00265-6 |
0.609 |
|
| 2001 |
Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, ... ... Stamatatos L, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. Journal of Virology. 75: 5526-40. PMID 11356960 DOI: 10.1128/JVI.75.12.5526-5540.2001 |
0.697 |
|
| 2001 |
Cherpelis S, Shrivastava I, Gettie A, Jin X, Ho DD, Barnett SW, Stamatatos L. DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques Journal of Virology. 75: 1547-1550. PMID 11152527 DOI: 10.1128/JVI.75.3.1547-1550.2001 |
0.38 |
|
| 2000 |
Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. Aids Research and Human Retroviruses. 16: 981-94. PMID 10890360 DOI: 10.1089/08892220050058407 |
0.47 |
|
| 2000 |
Ly A, Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. Journal of Virology. 74: 6769-76. PMID 10888615 DOI: 10.1128/JVI.74.15.6769-6776.2000 |
0.468 |
|
| 1998 |
Stamatatos L, Wiskerchen M, Cheng-Mayer C. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. Aids Research and Human Retroviruses. 14: 1129-39. PMID 9737584 DOI: 10.1089/aid.1998.14.1129 |
0.377 |
|
| 1998 |
Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. Journal of Virology. 72: 7840-5. PMID 9733820 DOI: 10.1128/jvi.72.10.7840-7845.1998 |
0.574 |
|
| 1997 |
Mo H, Stamatatos L, Ip JE, Barbas CF, Parren PW, Burton DR, Moore JP, Ho DD. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. Journal of Virology. 71: 6869-74. PMID 9261412 DOI: 10.1128/Jvi.71.9.6869-6874.1997 |
0.599 |
|
| 1997 |
Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells Virology. 229: 360-369. PMID 9126249 DOI: 10.1006/viro.1997.8443 |
0.668 |
|
| 1997 |
Cheng-Mayer C, Liu R, Landau NR, Stamatatos L. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. Journal of Virology. 71: 1657-61. PMID 8995695 DOI: 10.1128/jvi.71.2.1657-1661.1997 |
0.324 |
|
| 1995 |
Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology. 206: 878-84. PMID 7856100 DOI: 10.1006/Viro.1995.1010 |
0.447 |
|
| 1995 |
Stamatatos L, Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. Journal of Virology. 69: 6191-8. PMID 7545244 DOI: 10.1128/jvi.69.10.6191-6198.1995 |
0.45 |
|
| 1994 |
Stamatatos L, Werner A, Cheng-Mayer C. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. Journal of Virology. 68: 4973-9. PMID 8035496 DOI: 10.1128/Jvi.68.8.4973-4979.1994 |
0.485 |
|
| 1994 |
Stamatatos L, Levy JA. CD26 is not involved in infection of peripheral blood mononuclear cells by HIV-1. Aids (London, England). 8: 1727-8. PMID 7888123 |
0.395 |
|
| 1993 |
Stamatatos L, Cheng-Mayer C. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. Journal of Virology. 67: 5635-9. PMID 8350416 DOI: 10.1128/Jvi.67.9.5635-5639.1993 |
0.424 |
|
| 1991 |
Konopka K, Stamatatos L, Larsen CE, Davis BR, Düzgüneş N. Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions. The Journal of General Virology. 72: 2685-96. PMID 1940866 DOI: 10.1099/0022-1317-72-11-2685 |
0.548 |
|
| Show low-probability matches. |